ESOC 2021 | Future investigation avenues in CAA

Gargi Banerjee, BM BCh, MRCP, PhD, UCL Institute of Prion Diseases, University College London, London, UK, highlights the importance of replicating studies on cerebral amyloid angiopathy (CAA) across research groups and standardizing the method of measuring and quantifying biomarkers internationally. Dr Banerjee explains that clinical trials should focus on the collection of natural history data, to provide information on how biomarkers change during disease progression. For example, a study investigating Dutch CAA suggested that both cerebrospinal (CSF) and positron emission tomography (PET) amyloid-β (Aβ) markers showed changes in asymptomatic mutation carriers. It is therefore important to track these biomarkers throughout the course of the disease to gain a better understanding of how they might change over time and when to intervene with treatments. This interview took place at the European Stroke Organisation Conference (ESOC), 2021.